Medicare Enrolled
OIG Exclusion: cannot bill Medicare or Medicaid
This provider was excluded by the U.S. Office of Inspector General on
June 18, 2015
under section 1128a1
.
Currently active.
Verify on OIG.hhs.gov →
Dr. Eduardo Miranda, M.D.
Optician · Laredo, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Miranda from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Miranda?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Miranda
Dr. Eduardo Miranda is an optician specialist in Laredo, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Miranda performed 64,808 Medicare services across 1,068 unique beneficiaries.
Between the years covered by Open Payments, Dr. Miranda received a total of $29,885 from 95 pharmaceutical and/or device companies across 1496 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Miranda is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in TX
$29,885 industry payments
Medicare Practice Summary
Medicare Utilization ↗64,808
Medicare services
Top 1% in TX for optician
1,068
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,411 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
35,700 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 14,205 | $43 | $95 |
| Denosumab injection (Prolia/Xgeva) | 5,521 | $18 | $32 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,996 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 1,222 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,090 | $1 | $5 |
| Iron dextran injection, 50 mg An injection containing 50 mg of iron dextran administered to the patient. |
659 | $13 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
509 | $60 | $152 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
475 | $93 | $219 |
| Heparin sodium injection, per 1000 units An injection of heparin sodium, a blood thinner, administered in units of 1000. |
362 | $0 | $5 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
318 | $99 | $305 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
303 | $22 | $62 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
302 | $6 | $34 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
188 | $48 | $154 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
147 | $11 | $50 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
121 | $22 | $68 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
118 | $49 | $140 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
117 | $1 | $1 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
97 | $10 | $37 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
88 | $117 | $321 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
75 | $26 | $72 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 72 | $129 | $525 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
59 | $16 | $45 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
28 | $20 | $117 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
20 | $126 | $400 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
16 | $93 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
56.6% high complexity
41.6% medium
1.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$29,885
Total received (2018-2024)
Avg $4,269/year across 7 years
Top 7% in TX for optician
95
Companies
1,496
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,284 (87.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,386 (8.0%)
Other
Charitable contributions, space rental, and other categories
$1,215 (4.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,528
2023
$4,870
2022
$4,416
2021
$5,025
2020
$3,160
2019
$3,648
2018
$3,238
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$3,030
PFIZER INC.
$2,454
Janssen Biotech, Inc.
$1,786
AstraZeneca Pharmaceuticals LP
$1,739
Astellas Pharma US Inc
$1,581
Amgen Inc.
$1,354
Seagen Inc.
$1,139
Incyte Corporation
$1,113
Merck Sharp & Dohme Corporation
$914
Genentech USA, Inc.
$873
E.R. Squibb & Sons, L.L.C.
$795
Merck Sharp & Dohme LLC
$779
Celgene Corporation
$764
GENZYME CORPORATION
$760
Rigel Pharmaceuticals, Inc.
$658
Eisai Inc.
$552
Karyopharm Therapeutics Inc.
$420
GlaxoSmithKline, LLC.
$379
Regeneron Healthcare Solutions, Inc.
$361
Gilead Sciences, Inc.
$353
Exelixis Inc.
$326
Boehringer Ingelheim Pharmaceuticals, Inc.
$294
EISAI INC.
$265
Takeda Pharmaceuticals U.S.A., Inc.
$252
Bayer Healthcare Pharmaceuticals Inc.
$246
Puma Biotechnology, Inc.
$239
ARRAY BIOPHARMA INC
$238
MorphoSys, US Inc.
$234
Lilly USA, LLC
$227
JAZZ PHARMACEUTICALS INC.
$219
ADC Therapeutics America, Inc.
$215
Ipsen Biopharmaceuticals, Inc
$215
Melinta Therapeutics, Inc.
$208
AVEO Pharmaceuticals, Inc.
$203
SEAGEN INC.
$199
Kite Pharma, Inc.
$191
Daiichi Sankyo Inc.
$180
BeiGene USA, Inc.
$174
Dova Pharmaceuticals
$172
Bayer HealthCare Pharmaceuticals Inc.
$170
AMAG Pharmaceuticals, Inc.
$170
PUMA BIOTECHNOLOGY, INC.
$144
Taiho Oncology, Inc.
$136
SOBI, INC
$134
EMD Serono, Inc.
$133
ABBVIE INC.
$131
Janssen Pharmaceuticals, Inc
$121
Epizyme, Inc.,
$116
Janssen Scientific Affairs, LLC
$107
Octapharma USA, Inc.
$107
Sumitomo Pharma America, Inc.
$104
Spectrum Pharmaceuticals Inc.
$102
Aveo Pharmaceuticals, Inc.
$102
Agios Pharmaceuticals, Inc.
$99
AbbVie, Inc.
$99
Bolton Medical Inc
$95
Pharmacosmos Therapeutics Inc.
$95
McKesson Specialty Care Distribution, LLC
$89
TerSera Therapeutics LLC
$89
Alexion Pharmaceuticals, Inc.
$88
Stemline Therapeutics Inc.
$85
Foundation Medicine, Inc.
$83
Verastem, Inc.
$80
Coherus Biosciences Inc.
$73
Blueprint Medicines Corporation
$71
Sobi, Inc
$68
Tactile Systems Technology Inc
$67
Myovant Sciences Inc.
$64
Deciphera Pharmaceuticals Inc.
$62
Seattle Genetics, Inc.
$61
Mirati Therapeutics, Inc.
$57
Pharmacyclics LLC, An AbbVie Company
$49
Genmab U.S., Inc.
$42
RECORDATI_RARE_DISEASES_INC.
$37
Melinta Therapeutics, LLC
$34
Kyowa Kirin, Inc.
$34
Geron Corporation
$32
Tempus AI, Inc
$30
Immunocore Limited
$25
Teleflex LLC
$25
TESARO, Inc.
$23
CTI BioPharma Corp.
$23
AbbVie Inc.
$22
ImmunoGen, Inc.
$22
Mylan Institutional Inc.
$21
Organon LLC
$21
Acceleron Pharma, Inc.
$21
TAIHO ONCOLOGY, INC.
$21
TG Therapeutics, Inc.
$18
Array BioPharma Inc.
$16
Clovis Oncology, Inc.
$15
R-Pharm US LLC
$15
Dendreon Pharmaceuticals LLC
$13
Acrotech Biopharma LLC
$12
Secura Bio, Inc.
$11
Top 3 companies account for 24.3% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · ARROW · AYVAKIT · Alecensa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · ELREXFIO · EMEND · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Enhertu · Epkinly · Erleada · FERAHEME · FLEXITOUCH · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · FULPHILA · Fabhalta · Farydak · Flexitouch Plus · Folotyn · GAVRETO · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INVOKANA · Imbruvica · Ixempra · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · ORGOVYX · Ocrevus · Onivyde · Orbactiv · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM · ROLVEDON · RYBREVANT · RYDAPT · RYTELO · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · Vabomere · Vectibix · Venclexta · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 7% for optician in TX.
Equivalent to $46 per 100 Medicare services performed
Geographic Context
Opticians within 10 mi
11
Per 100K population
4.1
County median income
$62,506
Nearest hospital
DOCTORS HOSPITAL OF LAREDO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Miranda is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with low-engagement industry engagement in the top 7% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Miranda experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Miranda performed 35,700 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Miranda receive payments from pharmaceutical companies?
Yes. Dr. Miranda received a total of $29,885 from 95 companies across 1,496 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Miranda's costs compare to other opticians in Laredo?
Dr. Miranda's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Miranda) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Laredo
Browse opticians in Laredo ranked by procedure volume and transparency data.
Highest volume
Top Opticians in TX
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in TX
Which TX opticians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology